PS
Paul E. Sax
Highly rated in
9
conditions

Dr. Paul E. Sax

Brigham And Womens Hospital
Boston, MA
Highly rated in
9
conditions
Specialties:Infectious Disease
Experience:36 Years
Age:63
Clinical Trials:Currently Recruiting for 1 Trial
Accepts:New PatientsMedicare
Highly rated in
9
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Paul E. Sax's experience treating your condition:
About Dr. Paul E. Sax

Paul Sax is an Infectious Disease expert in Boston, Massachusetts. Sax has been practicing medicine for over 36 years and is highly rated in 9 conditions, according to our data. His top areas of expertise are HIV/AIDS, AIDS Dysmorphic Syndrome, Myelitis, and AIDS Dementia Complex. He is licensed to treat patients in Massachusetts. Sax is currently accepting new patients.

His clinical research consists of co-authoring 208 peer reviewed articles and participating in 11 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Paul E. Sax it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Paul E. Sax accepts the following insurance:

  •  Ambetter
  •  Anthem
Call to see if your plan is accepted.
Locations
75 Francis St, Boston, MA 02115
Background & Education
Graduate Institution
Harvard Medical School, 1987
Specialties
Infectious Disease
Licenses
Internal Medicine in MA
Hospital Affiliations
Massachusetts General Hospital
Brigham And Womens Hospital
Brigham And Womens Faulkner Hospital
Languages Spoken
English
Haitian
Spanish
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials
Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Enrollment Status: Recruiting
Publish Date: February 24, 2022
Intervention Type: Drug
Study Drugs: DoravirineTenofovir alafenamideEmtricitabineLamivudineIntegrase strand transfer inhibitorsTenofovir disproxil fumarate
Study Phase: Phase 4
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Active, not recruiting
Publish Date: December 08, 2022
Intervention Type: Drug
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Drug
Study Drugs: CabotegravirRilpivirineBIKTARVY
Study Phase: Phase 3
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Active, not recruiting
Publish Date: February 21, 2022
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Other, Drug
Study Phase: Phase 4
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Enrollment Status: Completed
Publish Date: August 06, 2021
Intervention Type: Drug
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Enrollment Status: Completed
Publish Date: August 03, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study
Enrollment Status: Completed
Publish Date: October 14, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 2
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Enrollment Status: Completed
Publish Date: April 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials -
208 Total Publications
Reply to Authors.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: September 08, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
MK
Michael Klompas
Dr. Michael Klompas
Infectious Disease
Highly rated in
9
conditions
Infectious Disease

Brigham Health

Brigham And Women's Hospital

75 Francis St, 
Boston, MA 

Michael Klompas is an Infectious Disease expert in Boston, Massachusetts. Klompas has been practicing medicine for over 23 years and is highly rated in 9 conditions, according to our data. His top areas of expertise are Hospital-Acquired Pneumonia, Pneumonia, Sepsis, and Toxic Shock Syndrome. He is licensed to treat patients in Massachusetts. Klompas is currently accepting new patients.

LC
Dr. Lin H. Chen
Infectious Disease
Highly rated in
14
conditions
Infectious Disease

Beth Israel Lahey Health

Mount Auburn Hospital

330 Mt Auburn St, 
Cambridge, MA 
 2.9 mi

Lin Chen is an Infectious Disease expert in Cambridge, Massachusetts. Chen has been practicing medicine for over 37 years and is highly rated in 14 conditions, according to our data. Her top areas of expertise are Yellow Fever, Viral Hemorrhagic Fever, Japanese Encephalitis, and Zika Virus Disease. She is licensed to treat patients in Massachusetts.

DB
Dan H. Barouch
Dr. Dan H. Barouch
Infectious Disease
Highly rated in
9
conditions
Infectious Disease

Beth Israel Lahey Health

Beth Israel Deaconess Medical Center

330 Brookline Ave, 
Boston, MA 
 0.3 mi

Dan Barouch is an Infectious Disease expert in Boston, Massachusetts. Barouch has been practicing medicine for over 24 years and is highly rated in 9 conditions, according to our data. His top areas of expertise are HIV/AIDS, COVID-19, Severe Acute Respiratory Syndrome (SARS), and Zika Virus Disease. He is licensed to treat patients in Massachusetts. Barouch is currently accepting new patients.